Optimal treatment intensification for glycaemic control in patients with type 2 diabetes on two oral agents: real world comparison of GLP-1, OADs and insulin

被引：0
|
作者：
Desouza, C. [1 ]
Kirk, A. Ross [2 ]
Mangla, K. Kant [3 ]
Wolden, M. Lyng [2 ]
Lingvay, I. [4 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE USA
[2] Novo Nordisk AS, Soborg, Denmark
[3] Novo Nordisk Serv Ctr India Pvt Ltd, Bangalore, Karnataka, India
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
596
引用
收藏
页码：S286 / S287
页数：2
相关论文
共 50 条
  • [41] Head to head comparison of glucagon-like peptide 1 (GLP-1) agonists and insulin in patients with Type 2 diabetes
    Siddiqi, Al
    Nambi, S.
    DIABETIC MEDICINE, 2013, 30 : 163 - 163
  • [42] EFFECT OF DAILY OR WEEKLY GLP-1 RECEPTOR AGONISTS ON GLYCEMIC CONTROL IN INSULIN-NAIVE PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES: A REAL-WORLD STUDY
    Singhal, M.
    Nguyen, H.
    Schauerhamer, M.
    Unni, S.
    Cobden, D.
    McAdam-Marx, C.
    VALUE IN HEALTH, 2015, 18 (03) : A54 - A54
  • [43] Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes
    Chen, Yongru
    Chen, Jingxian
    Zhang, Shuo
    Zhu, Dan
    Deng, Feiying
    Zuo, Rui
    Hu, Yufei
    Zhao, Yue
    Duan, Yale
    Lin, Benwei
    Chen, Fengwu
    Liang, Yun
    Zheng, Jiaxiong
    Khan, Barkat Ali
    Hou, Kaijian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] The impact of GLP-1 analogue liraglutide on type 2 diabetes patients with and without insulin therapy
    Haq, Z.
    Reidy, Y.
    Dempsey, M.
    Reidy, C.
    Keogh, A. M.
    Hoashi, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S491 - S492
  • [45] Beyond glycaemic control: reduced pneumonia and sepsis risk with GLP-1 RAs and SGLT2 inhibitors in patients with type 2 diabetes
    Rezaeianzadeh, Ramin
    Sadatsafavi, Mohsen
    THORAX, 2025, 80 (01) : 5 - 6
  • [46] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycaemic control and body weight in Japanese patients with type 2 diabetes
    Benson, C. T.
    Ohwaki, K.
    Furihata, K.
    Mimura, H.
    Oura, T.
    Imaoka, T.
    DIABETOLOGIA, 2019, 62 : S353 - S353
  • [47] GLP-1 for six weeks reduces weight and improves insulin sensitivity and glycemic control in patients with type 2 diabetes
    Zander, M
    Madsbad, S
    Holst, JJ
    DIABETES, 2001, 50 : A31 - A31
  • [48] Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus
    Shen, Yimei
    Yang, Xiaohua
    Han, Xiaojun
    Xi, Wei
    Jiang, Lihua
    Wang, Shuqin
    Zhong, Haifeng
    Gu, Yunjuan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11814 - 11823
  • [49] Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain
    Riebenfeld, Daniela
    Spirk, David
    Mathis, Alexandra
    Villiger, Lukas
    Gerber, Philipp A.
    Gasser, Urs Erwin
    Lehmann, Roger
    SWISS MEDICAL WEEKLY, 2015, 145
  • [50] HbA1c Trends with Treatment Intensification following Inadequate Response to Two Oral Agents in Patients with Type 2 Diabetes
    Kim, Kibum
    Unni, Sudhir
    Brixner, Diana
    Thomas, Sheila
    Olsen, Cody J.
    Sterling, Kimberly L.
    Mitchell, Matt
    Mcadam-Marx, Carrie
    DIABETES, 2018, 67
12345